Details for Patent: 11,795,176
✉ Email this page to a colleague
Which drugs does patent 11,795,176 protect, and when does it expire?
Patent 11,795,176 protects ZUNVEYL and is included in one NDA.
This patent has ten patent family members in nine countries.
Drugs Protected by US Patent 11,795,176
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alpha Cognition | ZUNVEYL | benzgalantamine gluconate | TABLET, DELAYED RELEASE;ORAL | 218549-001 | Jul 26, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE | ⤷ Sign Up | |||
| Alpha Cognition | ZUNVEYL | benzgalantamine gluconate | TABLET, DELAYED RELEASE;ORAL | 218549-002 | Jul 26, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE | ⤷ Sign Up | |||
| Alpha Cognition | ZUNVEYL | benzgalantamine gluconate | TABLET, DELAYED RELEASE;ORAL | 218549-003 | Jul 26, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,795,176
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2022208641 | ⤷ Sign Up | |||
| Canada | 3205859 | ⤷ Sign Up | |||
| China | 116761612 | ⤷ Sign Up | |||
| European Patent Office | 4029867 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
